Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

55X_ROI_Q1_2026 Aug. 19 at 9:28 PM

$MRNA @EingeLTrade $SLS Phase 2 mOS of > 67.6 months for GPS AML Remission Maintenance was better than Transplant ... Phase 3 Registrational Results are Now imminent... Something very similar to what happened for $MRNA will be Happening for SLS - ANY DAY NOW. Gps has proven effective in preventing relapse and extending survival, 2x 3x 4x - in ALL Prior Trials Including 2 for AML Remission Maintenance. While BAT / Aza+VEN / for the Control Arm recently Failed 3 Large Phase 3 AML Trials Conducted by $ABBV - including Failing the VIALE-M Maintenance for First Remission Patients, and Failed the VIALE-T Post Transplant Maintenance trial.

0 · Reply

biolover Aug. 19 at 6:02 PM

$LLY $NVO $VKTX BL is bypassing novo , $ABBV and going head to head against Lilly 😂. What the hell is he seeing on efficacy from phase 3 ? > 4500 pts been on drug > 1 year I know tolerability is pristine

1 · Reply

GoforProMIS Aug. 19 at 4:17 PM

$PMN CEO Neil Warma attended and presented at Jefferies Healthcare, Oppenheimer CNS and at the Bio International Conference with the opportunity of 1to1 meetings. As the Alzheimer Conference took place on on 12-15 July the 4-6 week NDA analyses by the specialist of pharmaceutical companies should be done. IMO we have 5-12 pharmaceutical companies interested in PMN: Biogen /Eisai due to high Aria of Leqembi. Roche as they lost bn with Gantenerumab and need a solution. $ABBV $BMY $NVS are keen to get into neurology as partnership. Pfizer and Takeda looking for Episelect Platform!

0 · Reply

55X_ROI_Q1_2026 Aug. 19 at 3:15 PM

$SLS Yes/ Just sub in GPs and for AML --- recall $MRK Dr. Julie Cohen in Co-Authoring and Publishing the GPS Key Phase 2 Results, Recommended running a Phase 3 for GPS and Keytruda in Plat Resistant Ovarian Cancer. GPs Key Phase 2 MOS was BETTER (18.4 months) than the FDA Approved $IMGN Elahere (16.4 months) in the same exact Patient setting. $ABBV Bought IMGN for $10B based on this Data. And GPS is better.

0 · Reply

MissionControl Aug. 19 at 2:10 PM

$ABBV Great morning surprise. 👀

0 · Reply

HawkEye828 Aug. 19 at 1:39 PM

Go Merck...PROK will easily blow past 95% once Rilparencel is appoved for Chronic Kidney disease. $PROK Analysts Sentiment Buy Price Target 6.250 Upside +369.92% prokidney.com/clinical-stud.... Phase 2 with 70% response rate for kidney disease. Phase 3 on deck. Riprencel cell therapy designed to delay or completely prevent the need for dialysis which is one of the highest Medicare expenses ...at $30 Billion a year/ 90k to 100k per patient. $RHHBY, $NVO, $LLY, $ABBV

0 · Reply

AXLFI_HQ Aug. 19 at 12:24 PM

$ABBV Companies are using acquisitions, divestitures, separations, and business combinations to gain scale, improve focus, unlock value, and optimize capital allocation. Learn more: https://axlfi.com/themes/379

0 · Reply

TMC101 Aug. 19 at 10:20 AM

$ABBV 🤔

0 · Reply

KarinSparrow145 Aug. 19 at 9:08 AM

$GENI $ABBV $SBET $DAL Genius Sports benefits from sports-data and betting partnerships, AbbVie benefits from diversified pharmaceutical demand, SBET remains highly speculative, and Delta benefits from travel demand and premium-airline activity. I'm watching contract growth, drug sales, funding, passenger demand, and margins.

0 · Reply

CDSTrading Aug. 19 at 8:57 AM

0 · Reply

Market Cap	442.28B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	22.95
Forward PE	17.73
Profit Margin	6.91%
Debt to Equity Ratio	-12.03

Volume	5,440,785
Avg Vol	6,944,488
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	99%
Beta	0.30
Analysts	Strong Sell
Price Target	$275.77